DK1734997T3 - Natalizumab til anvendelse ved behandling af sygdomme med behov for steroidbehandling - Google Patents

Natalizumab til anvendelse ved behandling af sygdomme med behov for steroidbehandling Download PDF

Info

Publication number
DK1734997T3
DK1734997T3 DK05768245.2T DK05768245T DK1734997T3 DK 1734997 T3 DK1734997 T3 DK 1734997T3 DK 05768245 T DK05768245 T DK 05768245T DK 1734997 T3 DK1734997 T3 DK 1734997T3
Authority
DK
Denmark
Prior art keywords
disease
natalizumab
steroid
antibody
human subject
Prior art date
Application number
DK05768245.2T
Other languages
English (en)
Inventor
Ivan Lieberburg
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1734997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK1734997T3 publication Critical patent/DK1734997T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (27)

1. Anvendelse af natalizumab eller et immunologisk aktivt fragment deraf til tilberedning af et medikament til at give et menneskeligt subjekt i en steroidsparende virksom mængde for reducering og/eller eliminering af et behov for steroidbehandling i det menneskelige subjekt med en sygdom valgt fra gruppen bestående af inflammatorisk tarmsygdom, astma, dissemineret sklerose, reumatoid artritis, host versus graft-sygdom, graft versus host-sygdom, spondyloartropatier og kombinationer deraf, hvori det menneskelige subjekt er under behandling med steroider.
2. Anvendelse ifølge krav 1, hvori natalizumab gives parenteralt til det menneskelige subjekt med behov derfor.
3. Anvendelse ifølge krav 1, hvori natalizumab gives kronisk til det menneskelige subjekt med behov derfor.
4. Anvendelse ifølge krav 2, hvori den parenterale indgivelse resulterer i en virksom natalizumabkoncentration i blodet på mindst 1 ng/ml i det menneskelige subjekt.
5. Anvendelse ifølge krav 4, hvori den virksomme natalizumabkoncentration i blodet er 1 ng/ml i det menneskelige subjekt.
6. Anvendelse ifølge krav 3, hvori den kroniske indgivelse af natalizumab er ugentlig eller månedlig over en periode på mindst et år.
7. Anvendelse ifølge krav 1, hvori sygdommen er inflammatorisk tarmsygdom, hvori natalizumab gives i en mængde, der virker til at tillade det menneskelige subjekt gradvist at mindske steroidterapi.
8. Anvendelse ifølge krav 7, hvori den inflammatoriske tarmsygdom er Crohns sygdom eller ulcerøs colitis.
9. Anvendelse ifølge krav 1, hvori sygdommen er dissemineret sklerose, hvori natalizumab gives i en mængde, der tillader det menneskelige subjekt gradvist at mindske steroidterapi.
10. Anvendelse ifølge krav 8 eller 9, hvori natalizumab gives til det menneskelige subjekt i en mængde på 2 mg/kg til 8 mg/kg.
11. Anvendelse ifølge krav 1, hvori sygdommen er reumatoid artritis, hvori natalizumab gives i en mængde, som er tilstrækkelig til at tillade det menneskelige subjekt gradvist at mindske steroidterapi.
12. Anvendelse ifølge krav 1, hvori sygdommen er host versus graft-sygdom eller graft versus host-sygdom, hvori natalizumab gives i en mængde, der tillader det menneskelige subjekt gradvist at mindske steroidterapi.
13. Anvendelse ifølge krav 1, hvori sygdommen er astma, hvori natalizumab gives i en mængde, der tillader det menneskelige subjekt gradvist at mindske steroidterapi.
13. Anvendelse ifølge krav 1, hvori sygdommen er spondyloartropati, hvori natalizumab gives i en mængde, der tillader det menneskelige subjekt gradvist at mindske steroidterapi.
15. Anvendelse ifølge krav 14, hvori spondyloartropatien er valgt fra gruppen bestående af spondylitis ankylopoietica, arthritis psoriatica, Reiters syndrom, spondylitis af inflammatorisk tarmsygdom, udifferentieret spondyloartropati og juvenil spondyloartropati.
16. Anvendelse ifølge ethvert af krav 7, 10, 11, 12, 13 eller 14, hvori det menneskelige subjekt er modstandsdygtigt overfor, intolerant overfor eller afhængigt af steroider.
17. Anvendelse ifølge krav 16, hvori det menneskelige subjekt kræver en terapeutisk virksom mængde steroider, der er mindre end hvad der ville kræves i fravær af indgivelse af natalizumab.
18. Anvendelse ifølge ethvert af krav 7, 10, 11, 12, 13 eller 14, hvori det menneskelige subjekt er: a) en patient, som ikke reagerer på eller er intolerant overfor behandling med immunundertrykkende midler; b) en patient, som ikke reagerer på, er intolerant overfor eller afhængig af behandling med steroider; eller c) en patient, der er en kombination af a) og b).
19. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestående af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA-sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af en inflammatorisk tarmsygdom, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
20. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestående af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA-sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af dissemineret sklerose, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
21. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestående af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA-sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af reumatoid artritis, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
22. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestående af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA-sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af host versus graft-sygdom eller graft versus host-sygdom, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
23. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestå- ende af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA- sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af astma, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
24. Anvendelse af en steroidsparende virksom mængde af natalizumab eller et immunologisk aktivt fragment deraf og et andet middel valgt fra gruppen bestående af: (i) et immunundertrykkende middel, hvori det immunundertrykkende middel ikke er et steroid; (ii) en anti-TNF-sammensætning; (iii) en 5-ASA- sammensætning; og (iv) kombinationer deraf til tilberedning af en medikamentkombination for kombinationsterapi af spondyloartropati, der skal gives for at reducere og/eller eliminere et behov for steroidbehandling i det menneskelige subjekt.
25. Anvendelse ifølge ethvert af krav 19-24, hvori kombinationsterapien omfatter en terapeutisk virksom mængde af et andet steroidsparende middel.
26. Anvendelse ifølge ethvert af krav 19-24, hvori det immunundertrykkende middel er valgt fra gruppen bestående af azathioprin, 6-mercaptopurin, metho-trexat og mycofenolat.
27. Anvendelse ifølge ethvert af krav 19-24, hvori anti-TNF-sammensætningen er infliximab.
28. Anvendelse ifølge ethvert af krav 19-24, hvori 5-ASA-sammensætningen er valgt fra gruppen bestående af sulfasalazin, mesalazin og osalazin.
DK05768245.2T 2004-04-01 2005-03-30 Natalizumab til anvendelse ved behandling af sygdomme med behov for steroidbehandling DK1734997T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55812004P 2004-04-01 2004-04-01
PCT/US2005/010848 WO2005099776A2 (en) 2004-04-01 2005-03-30 Steroid sparing agents and methods of using same

Publications (1)

Publication Number Publication Date
DK1734997T3 true DK1734997T3 (da) 2015-11-30

Family

ID=34972924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05768245.2T DK1734997T3 (da) 2004-04-01 2005-03-30 Natalizumab til anvendelse ved behandling af sygdomme med behov for steroidbehandling

Country Status (17)

Country Link
US (2) US20050260193A1 (da)
EP (1) EP1734997B1 (da)
JP (2) JP2007531761A (da)
AU (1) AU2005232571A1 (da)
CA (1) CA2561364C (da)
DK (1) DK1734997T3 (da)
ES (1) ES2554754T3 (da)
HU (1) HUE026236T2 (da)
IL (1) IL178302A (da)
MY (1) MY162179A (da)
NO (1) NO20064979L (da)
NZ (1) NZ594476A (da)
PL (1) PL1734997T3 (da)
PT (1) PT1734997E (da)
SI (1) SI1734997T1 (da)
TW (1) TWI462744B (da)
WO (1) WO2005099776A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210679A1 (en) 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
AU2012202575B2 (en) * 2004-11-19 2014-11-20 Biogen Ma Inc. Treatment for Multiple Sclerosis
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
AU2010279575B2 (en) 2009-08-03 2016-05-05 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
US8562589B2 (en) 2009-12-24 2013-10-22 Rani Therapeutics, Llc Swallowable drug delivery device and method of delivery
EP2543388A4 (en) * 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
AU2011261323A1 (en) * 2010-06-04 2013-01-24 The Brigham And Women's Hospital, Inc. Treatment of inflammatory disorders
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) * 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
NO2543357T3 (da) * 2011-07-07 2018-08-18
MX366936B (es) * 2011-11-23 2019-07-31 Amgen Inc Uso de un anticuerpo específico alfa4beta7.
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US10738121B2 (en) 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
JP7470646B2 (ja) * 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
WO2021242961A1 (en) * 2020-05-27 2021-12-02 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU2505599A (en) * 1998-02-10 1999-08-30 Cangene Corporation Method for the prevention and treatment of a type i hypersensitivity disorder
CN100369903C (zh) * 2000-06-30 2008-02-20 大日本住友制药株式会社 五元环化合物
US6794506B2 (en) * 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
AU2002306651B2 (en) * 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
US20030008844A1 (en) * 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
DE02782887T1 (de) * 2001-10-19 2005-01-13 Centre Hospitalier Regional et Universitair de Tours Methoden und kompositionen, antikörper behandlung zu bewerten
US6878518B2 (en) * 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
SI1485127T1 (sl) * 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
UY28170A1 (es) 2003-01-24 2004-07-30 Elan Pharm Inc Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same

Also Published As

Publication number Publication date
ES2554754T3 (es) 2015-12-23
NZ594476A (en) 2013-04-26
PT1734997E (pt) 2015-12-22
WO2005099776A2 (en) 2005-10-27
EP1734997A2 (en) 2006-12-27
US20150056205A1 (en) 2015-02-26
TWI462744B (zh) 2014-12-01
IL178302A (en) 2016-03-31
AU2005232571A1 (en) 2005-10-27
MY162179A (en) 2017-05-31
TW200602080A (en) 2006-01-16
SI1734997T1 (sl) 2016-02-29
CA2561364C (en) 2016-11-08
WO2005099776A9 (en) 2005-12-01
CA2561364A1 (en) 2005-10-27
PL1734997T3 (pl) 2016-02-29
JP2007531761A (ja) 2007-11-08
HUE026236T2 (en) 2016-06-28
US20050260193A1 (en) 2005-11-24
WO2005099776A3 (en) 2006-05-18
JP2013166765A (ja) 2013-08-29
IL178302A0 (en) 2008-03-20
EP1734997B1 (en) 2015-09-02
NO20064979L (no) 2007-01-02
HK1102663A1 (zh) 2007-11-30

Similar Documents

Publication Publication Date Title
CA2561364C (en) Steroid sparing agents and methods of using same
EP1278543B1 (en) Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
EP2484381A1 (en) Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US20140234299A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
AU2011213878B2 (en) Steroid sparing agents and methods of using same
HK1102663B (en) Natalizumab for use in treating diseases needing steroid treatment
HK40013033A (en) Composition for a treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1700606A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
HK1054320B (en) Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease
AU3759700A (en) Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
HK1155394B (en) Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease
HK1155394A (en) Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease
HK1094948A (en) Therapies for chronic renal failure using one or more integrin antagonists